| 쇼그랜 증후군의 최신 치료동향 |
|
김진석 |
|
제주대학교 의학전문대학원 내과학교실 |
| Novel therapeutic agents for Sjögren ’s syndrome |
|
Jinseok Kim |
|
Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea |
Correspondence:
Jinseok Kim, Email: slera@jejunu.ac.kr
|
|
|
| Abstract |
|
Sjögren ’s syndrome (SS) is a chronic autoimmune disorder of the exocrine gland that predominantly affects salivary and lacrimal glands. The principal target is the tubular epithelium of salivary and lacrimal glands, leading to the characteristic symptoms of dry eyes and mouth. The decreased functional capacity. of the lacrimal and salivary glands which is the result of the inflammatory process and Iymphocytic infiltration observed in SS. SS is one of the three most common autoimmune disorders. but there are currently no effective systemic therapies. Recent studies have broadened our understanding of the etiopathogenesis and immunopathology of primary SS. Systemic therapy includes treatment of the underlying systemic disorder with steroidal and non-steroidal agents, disease modifying drugs, and cytotoxic therapy to address the extra glandular manifestations. In spite of intensive research in other systemic treatments including biologic therapies，there is limited evidence to support their use in routine clinical practice. This article reviews existing data on the use of local and systemic treatments for glandular and extraglandular manifestations of primary SS |
| Key Words:
Sjogren’s syndrome; Tumor necrosis factor-alpha; Riluximab |
|
PDF Links
Full text via DOI
Download Citation
